Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Filing Date: February 27, 2015
Accounting Basis: International Financial Reporting Standards (IFRS)
GSK is a global pharmaceutical, vaccine, and consumer healthcare company. The 2014 reporting period was characterized by significant strategic restructuring, including a major transaction with Novartis AG to reorganize its Consumer Healthcare and Oncology businesses, alongside ongoing challenges from patent expirations and generic competition.
Key Financial Metrics (2014)
| Metric | 2014 Value | 2013 Value (Restated) |
|---|---|---|
| Turnover | £25,602 million | £26,505 million |
| Core Operating Profit | £6,594 million | £8,015 million |
| Total Operating Profit | £3,597 million | £7,028 million |
| Core Profit After Tax | £4,806 million | £5,671 million |
| Total Profit After Tax | £2,831 million | £5,628 million |
| Core Earnings Per Share (EPS) | 95.4p | 112.2p |
| Total EPS | 57.3p | 112.5p |
| Core R&D Expenditure | £3,113 million | £3,400 million |
| Net Debt | Not explicitly stated for 2014 in text; 2013 was £1.4 billion lower than 2012 | Decreased by £1.4 billion in 2013 |
| Dividend Per Share | 78p (2013 data provided; 2014 dividend not explicitly detailed in summary tables) | 78p |
Note: The provided text contains detailed reconciliation tables for 2014, 2013, and 2012. The 2014 Total Profit After Tax of £2,831 million reflects significant non-core charges.
Material Changes vs. Prior Period
- Revenue Decline: Total turnover decreased from £26,505 million in 2013 to £25,602 million in 2014. This decline was driven by the impact of divestments, generic competition, and pricing pressures, particularly in the US and Europe.
- Profitability Compression: Total operating profit fell significantly from £7,028 million in 2013 to £3,597 million in 2014. This was primarily due to non-core charges totaling approximately £2.9 billion, including major restructuring costs, legal charges, and intangible impairments.
- Core Performance: Core operating profit declined from £8,015 million (2013) to £6,594 million (2014). Core operating margin decreased to 25.8% in 2014 from 30.2% in 2013.
- Segment Performance:
- Pharmaceuticals: Sales were impacted by the loss of exclusivity for key products like Seretide/Advair in various markets and generic competition.
- Vaccines: Sales were affected by supply constraints and the suspension of HPV vaccine recommendations in Japan.
- Consumer Healthcare: Turnover was impacted by supply issues for key products like alli and Bactroban.
- Restructuring: The company continued its "Major Change" and "Operational Excellence" programs, incurring significant costs to simplify the supply chain and reduce overhead.
Guidance, Outlook, Risks, and Unusual Items
Strategic Transaction with Novartis
A material development in 2014 was the agreement with Novartis AG (announced April 2014) to:
- Create a joint venture combining GSK's Consumer Healthcare business with Novartis's OTC business (GSK to hold 63.5% stake).
- Sell GSK's Oncology business to Novartis for approximately US$16 billion.
- Purchase Novartis's Vaccines business (excluding influenza) for up to US$7.055 billion.
- Receive a put option for Novartis's influenza vaccines business.
The transaction received regulatory clearance from the US FTC and EU Commission in late 2014/early 2015 and was expected to close in March 2015.
Key Risks and Contingencies
- Legal Proceedings: GSK faced significant legal risks, including a 2014 verdict in China where GSK China Investment Co. Ltd. was found guilty of bribing non-government personnel, resulting in a fine of RMB 3 billion (£301 million). The company also faced ongoing US and UK investigations into anti-bribery and corruption (ABAC) matters.
- Patent Expirations: The company highlighted the risk of patent cliffs, specifically for Seretide/Advair (18% of global sales), which faces generic competition in the US and Europe. Loss of exclusivity leads to rapid sales declines.
- Supply Chain: Disruptions in 2014 affected Consumer Healthcare (alli, Bactroban) and Vaccines (hepatitis, Boostrix) due to manufacturing and quality control issues.
- Regulatory Environment: Increased scrutiny on pricing, promotion, and data integrity globally poses risks to revenue and reputation.
Unusual Items
- Intangible Impairments: Significant write-downs occurred, including partial impairment of Lovaza and write-offs of R&D assets.
- Legal Charges: Provisions for product liability and government investigations contributed to the reduction in total profit.
- Restructuring Costs: Major restructuring charges of £750 million were recorded in 2014.
Investor Verification Checklist
- Novartis Transaction Closing: Verify the final closing date and any adjustments to the purchase/sale prices for the Oncology, Vaccines, and Consumer Healthcare businesses.
- Legal Settlements: Monitor the status and potential financial impact of ongoing US and UK anti-bribery investigations and the Chinese bribery fine payment.
- Patent Cliff Impact: Assess the actual sales erosion of Seretide/Advair and other key products as generic competitors enter the US and European markets.
- Supply Chain Resolution: Confirm that manufacturing and supply issues for key Consumer Healthcare and Vaccine products have been fully resolved.
- Core Margin Recovery: Track the trajectory of core operating margins to determine if cost-saving initiatives are offsetting revenue declines.
- Dividend Policy: Verify the declared dividend for 2014 and the Board's commitment to maintaining the dividend payout ratio post-restructuring.